Analgesics for Osteoarthritis—An Update
Clinical Questions Addressed by the CER (1 of 2)
In preparing the report on which this continuing medical education (CME) activity is based, the authors aimed to answer four Key Questions (KQs). KQs 1 and 2 are listed below:
KQ 1: What are the comparative benefits and adverse effects of treating osteoarthritis with oral medications or supplements? How do these benefits and adverse effects change with dosage and duration of treatment?
- The only benefits considered here are improvements in osteoarthritic symptoms.
KQ2: Do the comparative benefits and adverse effects of oral treatmentsfor osteoarthritis vary for certain demographic and clinical subgroups of patients?
- Demographic subgroups: age, sex, and race
- Coexisting diseases: cardiovascular (CV) conditions, such as hypertension, edema, ischemic heart disease, heart failure; peptic ulcer disease; history of previous gastrointestinal bleeding (any cause); renal disease; hepatic disease; diabetes; and obesity
- Concomitant medication use: antithrombotics, corticosteroids, antihypertensives, selective serotonin-reuptake inhibitors (SSRIs)
- Chou R, McDonagh M, Nakamoto E, et al. Comparative Effectiveness and Safety of Analgesics for Osteoarthritis: An Update of the 2006 Report. Comparative Effectiveness Review No. 38 (Prepared by Oregon Evidence-based Practice Center under Contract No. HHSA 290-2007-10057-I). Rockville, MD: Agency for Healthcare Research and Quality; October 2011. AHRQ Publication No. 11(12)-EHC076-EF. Available at: http://www.effectivehealthcare.ahrq.gov/reports/analgesicsupdate.cfm.
Your slide tray is being processed.